PRODUCTS
Multi Plex Matrix MPM-FL0507
Indication: HYPERGLYCEMIA
MPM-FL0507 normalizes the fasting insulin/glucose ratio (FIGR) in a prevention mode.
MPM-FL0507 was tested for blood glucose regulation in high-fat models and high-fructose animal models (obesity induced insulin resistance).
MPM-FL0507 lowers the HOMA index in both preventive and therapeutic action.
MPM-FL0507 increases the insulin production leading to an enhancement of blood glucose metabolism.
MPM-FL0507 increases blood glucose metabolism suggesting a prevention of type 2 diabetes development.
MPM-FL0507 modulates the gene expression of PPARa and PPARg in liver indicating an important preventing effect in the development of type 2 diabetes.
Technical Targeted Health Claim
To help achieve and maintain homeostasis of glucose management
Fasting glucose/insulin ratio (FGIR) of hamsters on a high fat high cholesterol diet (HFHC) treated or not with MPM-FL0507 after 8 weeks.
Plasma Glucose AUC of Wistar rats on a high-fructose diet treated or not treated with MPM-FL0507 or Metformin.